EPRS Insider Trading Activity and SEC Form 4 Filings
EPRS insider trading summary
No open-market insider purchases or sales of EPIRUS Biopharmaceuticals, Inc. (EPRS) have been reported on SEC Form 4 in the past 12 months.
Latest EPRS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 21, 2015 | Robert Ticktin | General Counsel | Buy | $11K (3,000 @ $3.72) |
| Dec 17, 2015 | Aurentz Vincent | Chief Business Officer | Buy | $8K (2,200 @ $3.43) |
| Dec 16, 2015 | Amit Munshi | Chief Executive Officer | Buy | $23K (8,270 @ $2.80) |
| Dec 15, 2015 | Amit Munshi | Chief Executive Officer | Buy | $23K (8,069 @ $2.87) |
| Dec 9, 2015 | Amit Munshi | Chief Executive Officer | Buy | $54K (13,190 @ $4.07) |
| Dec 9, 2015 | Aurentz Vincent | Chief Business Officer | Buy | $11K (2,800 @ $3.85) |
| Sep 21, 2015 | Amit Munshi | Chief Executive Officer | Buy | $62K (10,000 @ $6.19) |
| Sep 18, 2015 | Amit Munshi | Chief Executive Officer | Buy | $60K (10,000 @ $5.99) |
| Feb 6, 2015 | Montreux Equity Partners IV LP | 10% Owner | Sell | $501K (100,000 @ $5.01) |
| Feb 6, 2015 | Montreux Equity Partners V, L.P. | 10% Owner | Sell | $501K (100,000 @ $5.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.